Safety of Enalapril in Infants : Data from the Pediatric Heart Network Infant Single Ventricle Trial
Copyright © 2020 Elsevier Inc. All rights reserved..
OBJECTIVE: To assess the safety profile of angiotensin-converting enzyme inhibitor therapy in infants with single ventricle.
STUDY DESIGN: The Pediatric Heart Network conducted a double-blind trial involving infants with single ventricle physiology randomized to receive enalapril or placebo and followed to 14 months of age. Data including demographics, drug administration, hemodynamic monitoring, laboratory measurements, adverse events, and survival were extracted from the public use data set and compared between the placebo and enalapril-treated groups.
RESULTS: The Infant Single Ventricle trial randomized 230 patients, with 115 patients in each group. Initial enalapril dose was 0.10 mg/kg/d and median maximal dose was 0.38 mg/kg/d. There was no significant difference in change in blood pressure at study drug initiation or when resuming study drug after Glenn surgery. The incidence of hyperkalemia and neutropenia did not differ between groups. Renal dysfunction occurred in 3% of the enalapril group and none of the placebo patients, which was not statistically significant. There was a high frequency of serious adverse events in both groups. There was no difference in the frequency of heart transplant or death between groups.
CONCLUSIONS: Enalapril did not have sustained hemodynamic effects at initiation or up-titration of drug. Creatinine and potassium were not different between groups, although renal dysfunction occurred more often in the patients on enalapril. Although efficacy of enalapril in neonates with single ventricle has not been demonstrated, the safety profile of angiotensin-converting enzyme inhibitors appears to be low risk in infants and children with significant heart disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:227 |
|---|---|
| Enthalten in: |
The Journal of pediatrics - 227(2020) vom: 28. Dez., Seite 218-223 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mathur, Kanika [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.01.2021 Date Revised 28.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jpeds.2020.07.058 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM313434956 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM313434956 | ||
| 003 | DE-627 | ||
| 005 | 20231225150550.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jpeds.2020.07.058 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1044.xml |
| 035 | |a (DE-627)NLM313434956 | ||
| 035 | |a (NLM)32768465 | ||
| 035 | |a (PII)S0022-3476(20)30957-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mathur, Kanika |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Safety of Enalapril in Infants |b Data from the Pediatric Heart Network Infant Single Ventricle Trial |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.01.2021 | ||
| 500 | |a Date Revised 28.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier Inc. All rights reserved. | ||
| 520 | |a OBJECTIVE: To assess the safety profile of angiotensin-converting enzyme inhibitor therapy in infants with single ventricle | ||
| 520 | |a STUDY DESIGN: The Pediatric Heart Network conducted a double-blind trial involving infants with single ventricle physiology randomized to receive enalapril or placebo and followed to 14 months of age. Data including demographics, drug administration, hemodynamic monitoring, laboratory measurements, adverse events, and survival were extracted from the public use data set and compared between the placebo and enalapril-treated groups | ||
| 520 | |a RESULTS: The Infant Single Ventricle trial randomized 230 patients, with 115 patients in each group. Initial enalapril dose was 0.10 mg/kg/d and median maximal dose was 0.38 mg/kg/d. There was no significant difference in change in blood pressure at study drug initiation or when resuming study drug after Glenn surgery. The incidence of hyperkalemia and neutropenia did not differ between groups. Renal dysfunction occurred in 3% of the enalapril group and none of the placebo patients, which was not statistically significant. There was a high frequency of serious adverse events in both groups. There was no difference in the frequency of heart transplant or death between groups | ||
| 520 | |a CONCLUSIONS: Enalapril did not have sustained hemodynamic effects at initiation or up-titration of drug. Creatinine and potassium were not different between groups, although renal dysfunction occurred more often in the patients on enalapril. Although efficacy of enalapril in neonates with single ventricle has not been demonstrated, the safety profile of angiotensin-converting enzyme inhibitors appears to be low risk in infants and children with significant heart disease | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a angiotensin-converting enzyme inhibitor | |
| 650 | 4 | |a congenital heart disease | |
| 650 | 4 | |a heart failure | |
| 650 | 7 | |a Angiotensin-Converting Enzyme Inhibitors |2 NLM | |
| 650 | 7 | |a Enalapril |2 NLM | |
| 650 | 7 | |a 69PN84IO1A |2 NLM | |
| 700 | 1 | |a Hsu, Daphne T |e verfasserin |4 aut | |
| 700 | 1 | |a Lamour, Jacqueline M |e verfasserin |4 aut | |
| 700 | 1 | |a Aydin, Scott I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of pediatrics |d 1945 |g 227(2020) vom: 28. Dez., Seite 218-223 |w (DE-627)NLM000019003 |x 1097-6833 |7 nnns |
| 773 | 1 | 8 | |g volume:227 |g year:2020 |g day:28 |g month:12 |g pages:218-223 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jpeds.2020.07.058 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 227 |j 2020 |b 28 |c 12 |h 218-223 | ||